A new analysis of a group of patients with advanced metastatic melanoma treated with peptide vaccines after surgery shows an average survival of nearly 4 years -- far longer than seen in previous trials.
A new analysis of a group of patients with advanced metastatic melanoma treated with peptide vaccines after surgery shows an average survival of nearly 4 years -- far longer than seen in previous trials.
